Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Study Suggests Capitalizing on the Glioblastoma Tropism of Mesenchymal Stem Cells for the Targeted Treatment of Brain Cancer

By BiotechDaily International staff writers
Posted on 25 Mar 2013
Mesenchymal stem cells (MSCs) obtained from adipose tissue migrate to sites of injury in the body and potentially may be developed into a delivery system for anticancer drugs targeted at glioblastoma cells remaining after surgical removal of a primary tumor.

In a proof-of-principle study investigators at Johns Hopkins University (Baltimore, MD, USA) compared the cancer cell tropism of MSCs from adipose tissue to that of MSCs from bone marrow. The rationale behind the study was that since MSCs from adipose tissue are more abundant and more easily obtained than those from bone marrow are, a similar degree of glioblastoma tropism would encourage further research into the possible use of adipose tissue MSCs.

The investigators established cultures of MSCs from adipose tissue (AMSCs) and characterized them for cell surface markers of mesenchymal stem cell origin in conjunction with the potential for differentiation into fat, bone, and cartilage. Validated AMSCs produced at Johns Hopkins were then compared to commercially obtained human bone marrow MSCs (BMSCs) and AMSCs for growth responsiveness and glioma tropism in response to glioma conditioned media obtained from primary gliomaneurosphere cultures.

Results published in the March 12, 2013, online edition of the journal PLOS ONE revealed that commercial and primary culture AMSCs and commercial BMSCs demonstrated no statistically significant difference in their migration towards glioma conditioned media in vitro. There was statistically significant difference in the proliferation rate of both commercial AMSCs and BMSCs as compared to primary culture AMSCs, suggesting primary cultures have a slower growth rate than commercially available cell lines.


"The biggest challenge in brain cancer is the migration of cancer cells. Even when we remove the tumor, some of the cells have already slipped away and are causing damage somewhere else," said senior author Dr. Alfredo Quinones-Hinojosa, professor of neurosurgery, oncology, and neuroscience at Johns Hopkins University. "Building off our findings, we may be able to find a way to arm a patient's own healthy cells with the treatment needed to chase down those cancer cells and destroy them. It is truly personalized medicine."

Related Links:
Johns Hopkins University





comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: Neurons (greenish yellow) attach to silk-based scaffold (blue) creating functional networks throughout the scaffold pores (dark areas) (Photo courtesy of Tufts University).

Functional 3D Brain-Like Tissue Model Bioengineered

Researchers recently reported on the development of the first complex, three-dimensional (3D) model comprised of brain-like cortical tissue that displays biochemical and electrophysiologic responses, and... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.